Tumor cell antigen presented via MHC class II

Tumor cell antigen presented via MHC class II" refers to fragments of tumor-associated or tumor-specific proteins (peptides) displayed on the surface of cells in complex with MHC class II molecules. Under physiological conditions, MHC class II is constitutively expressed on professional antigen-presenting cells (APCs) such as dendritic cells, macrophages, and B cells. These molecules present exogenously acquired peptides (including those from tumor debris or secreted products) to CD4+ T helper cells, which orchestrate and potentiate anti-tumor immune responses[6][7][8]. However, certain tumor cells, under the influence of cytokines like interferon gamma or through epigenetic modification, may also express MHC class II and directly present endogenous or exogenous tumor antigens, potentially stimulating CD4+ T cell-mediated anti-tumor immunity[5][7]. Constitutive or IFN-γ-induced expression of MHC class II in tumor cells or tumor-associated fibroblasts has been correlated with improved prognosis and response to immune checkpoint blockade therapies in cancer patients, likely by expanding the repertoire of antigen presentation and inducing robust T helper cell responses[5]. While not a single protein or receptor, but rather a peptide–MHC complex, targeting the process or enhancing the presentation of tumor antigens via MHC class II remains a key strategy in immunotherapy research. Core challenges include controlling specificity, minimizing autoimmunity, and increasing tumor-specific antigen presentation.

Other names

Tumor antigens presented by MHC class IIMHC-II-restricted tumor antigensPeptide-MHC class II complexes (tumor-derived)Tumor MHC-II antigens

Indirect—promoting CD4+ T cell activation by increasing MHC-II expression on tumor cells; no direct ligand/drug for antigens themselves